Back to search results

Observational Study of Ablative Radiotherapy for Metastatic Cancer

This study is creating a registry of patients with metastatic cancer (cancer that has spread to other parts of the body) who are receiving or have received ablative radiotherapy. Ablative radiotherapy is a type of radiation therapy that delivers a high dose of radiation to a specific area. The main goal is to track how often patients experience acute adverse events (side effects that happen soon after treatment) after receiving this treatment. You may be able to join if you are 18 or older, have metastatic disease, and are planning to receive, currently receiving, or have completed ablative radiotherapy to a site outside of your brain. The study is currently unclear on its recruitment status and plans to include about 300 participants.

Study design
This is an observational study, meaning researchers will collect information without giving any specific intervention. It aims to enroll 300 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track acute adverse events for 90 days after radiotherapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04085029

Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Recruiting
Not specifiedAges 18+Observational
Duke University
~300 participants
Updated 2026-02-05 on ClinicalTrials.gov

At a glance

Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Occurrence of acute adverse events following radiotherapy
Measured over 90 Days

Conditions

Oligometastasis
Metastatic Cancer

Explore related trials

Metastatic Malignant Neoplasm

NCT04085029

Where you'd take part

This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Duke Cancer Institute Cary

    Cary, North Carolinastudy coordinator listed

    Recruiting

  • Duke Raleigh Hospital

    Raleigh, North Carolinastudy coordinator listed

    Recruiting

  • Duke University Medical Center

    Durham, North Carolinastudy coordinator listed

    Recruiting

  • Duke Women's Cancer Care Raleigh

    Raleigh, North Carolinastudy coordinator listed

    Recruiting

  • Durham Veterans Administration Health Care System (DVAHCS)

    Durham, North Carolinastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Joseph Salama, MD · PRINCIPAL_INVESTIGATOR · Duke University

Who to contact

Clinical Trials Office
[email protected]
(919) 668 3726
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years of age
Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
Patient must sign study-specific informed consent

What this trial measures

  • Occurrence of acute adverse events following radiotherapy90 Days